Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Non-Current Liabilities data on file, last reported at $26.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 13.06% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (down 13.06% YoY) and the FY2025 annual result came in at $30.8 million, down 6.65% from the prior year.
• Total Non-Current Liabilities retreated to $26.3 million in Q1 2026 per MXCT's latest filing, from $30.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $35.8 million in Q4 2023 and bottomed at $26.3 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $31.3 million (2022), against an average of $31.2 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities jumped 144.74%; it then decreased 13.06% in 2026.
• Tracing MXCT's Total Non-Current Liabilities over 5 years: stood at $31.4 million in 2022, then rose by 14.22% to $35.8 million in 2023, then retreated by 8.04% to $32.9 million in 2024, then retreated by 6.65% to $30.8 million in 2025, then dropped by 14.4% to $26.3 million in 2026.
• Per Business Quant, the three latest MXCT Total Non-Current Liabilities figures stand at $26.3 million (Q1 2026), $30.8 million (Q4 2025), and $33.0 million (Q3 2025).

Peer Comparison